Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. (Q41697696)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 December 2014

Language	Label	Description	Also known as
English	Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.	scientific article published on 15 December 2014

Statements

scholarly article

1 reference

Europe PubMed Central

7 October 2017

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. (English)

1 reference

Europe PubMed Central

7 October 2017

0 references

author name string

M Kim

1

1 reference

Europe PubMed Central

7 October 2017

J Park

2

1 reference

Europe PubMed Central

7 October 2017

D-W Kim

3

1 reference

Europe PubMed Central

7 October 2017

Y-J Kim

4

1 reference

Europe PubMed Central

7 October 2017

Y-W Jeon

5

1 reference

Europe PubMed Central

7 October 2017

J-H Yoon

6

1 reference

Europe PubMed Central

7 October 2017

S-H Shin

7

1 reference

Europe PubMed Central

7 October 2017

S-A Yahng

8

1 reference

Europe PubMed Central

7 October 2017

S-E Lee

9

1 reference

Europe PubMed Central

7 October 2017

B-S Cho

10

1 reference

Europe PubMed Central

7 October 2017

K-S Eom

11

1 reference

Europe PubMed Central

7 October 2017

H-J Kim

12

1 reference

Europe PubMed Central

7 October 2017

C-Ki Min

13

1 reference

Europe PubMed Central

7 October 2017

S-G Cho

14

1 reference

Europe PubMed Central

7 October 2017

Y Kim

15

1 reference

Europe PubMed Central

7 October 2017

J-W Lee

16

1 reference

Europe PubMed Central

7 October 2017

K Han

17

1 reference

Europe PubMed Central

7 October 2017

W-S Min

18

1 reference

Europe PubMed Central

7 October 2017

S Lee

19

1 reference

Europe PubMed Central

7 October 2017

language of work or name

0 references

publication date

15 December 2014

1 reference

Europe PubMed Central

7 October 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

7 October 2017

50

1 reference

Europe PubMed Central

7 October 2017

354-362

1 reference

Europe PubMed Central

7 October 2017

3

1 reference

Europe PubMed Central

7 October 2017

https://scigraph.springernature.com/pub.10.1038/bmt.2014.281

0 references

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2014.281

1 reference

Europe PubMed Central

7 October 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41697696&oldid=1540629629"